{"title":"全球免疫-营养-信息指数是接受根治性治疗的胃癌患者的独立预后因素","authors":"Toru Aoyama, Itaru Hashimoto, Yukio Maezawa, Kentaro Hara, Sosuke Yamamoto, Ryuki Esashi, Ayako Tamagawa, Haruhiko Cho, Mie Tanabe, Jyunya Morita, Masakatsu Numata, Shinnosuke Kawahara, Takashi Oshima, Aya Saito, Norio Yukawa","doi":"10.21873/cdp.10353","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aim: </strong>The aim of the present study was to evaluate the clinical impact of the Global Immune-Nutrition-Information Index (GINI) in patients with gastric cancer (GC) who received curative treatment and to clarify the potential of the GINI as a biomarker.</p><p><strong>Patients and methods: </strong>Patients who underwent curative resection for GC at Yokohama City University between 2005 and 2020 were selected based on their medical records. The GINI was calculated as follows: GINI=[C-reactive protein × platelet × monocyte × neutrophil]/[albumin × lymphocyte].</p><p><strong>Results: </strong>A total of 258 patients were included in this study. Of these, 169 patients were categorized into the GINI-low group and 89 into the GINI-high group using a cut-off value of 1,730. The three- and five-year overall survival (OS) rates were 86.4% and 78.4%, respectively, in the GINI-low group, and 66.4% and 58.3% in the GINI-high group (p<0.001). In a multivariate analysis for OS, the GINI was identified as an independent prognostic factor [hazard ratio (HR)=1.772; 95% confidence interval (CI)=1.053-2.979, p=0.031]. Similar results were observed for RFS. In addition, the GINI affected the perioperative clinical course, including postoperative surgical complications and postoperative adjuvant treatment.</p><p><strong>Conclusion: </strong>The GINI is a promising biomarker for the treatment and management of GC.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11215449/pdf/","citationCount":"0","resultStr":"{\"title\":\"Global Immune-Nutrition-Information Index Is Independent Prognostic Factor for Gastric Cancer Patients Who Received Curative Treatment.\",\"authors\":\"Toru Aoyama, Itaru Hashimoto, Yukio Maezawa, Kentaro Hara, Sosuke Yamamoto, Ryuki Esashi, Ayako Tamagawa, Haruhiko Cho, Mie Tanabe, Jyunya Morita, Masakatsu Numata, Shinnosuke Kawahara, Takashi Oshima, Aya Saito, Norio Yukawa\",\"doi\":\"10.21873/cdp.10353\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background/aim: </strong>The aim of the present study was to evaluate the clinical impact of the Global Immune-Nutrition-Information Index (GINI) in patients with gastric cancer (GC) who received curative treatment and to clarify the potential of the GINI as a biomarker.</p><p><strong>Patients and methods: </strong>Patients who underwent curative resection for GC at Yokohama City University between 2005 and 2020 were selected based on their medical records. The GINI was calculated as follows: GINI=[C-reactive protein × platelet × monocyte × neutrophil]/[albumin × lymphocyte].</p><p><strong>Results: </strong>A total of 258 patients were included in this study. Of these, 169 patients were categorized into the GINI-low group and 89 into the GINI-high group using a cut-off value of 1,730. The three- and five-year overall survival (OS) rates were 86.4% and 78.4%, respectively, in the GINI-low group, and 66.4% and 58.3% in the GINI-high group (p<0.001). In a multivariate analysis for OS, the GINI was identified as an independent prognostic factor [hazard ratio (HR)=1.772; 95% confidence interval (CI)=1.053-2.979, p=0.031]. Similar results were observed for RFS. In addition, the GINI affected the perioperative clinical course, including postoperative surgical complications and postoperative adjuvant treatment.</p><p><strong>Conclusion: </strong>The GINI is a promising biomarker for the treatment and management of GC.</p>\",\"PeriodicalId\":72510,\"journal\":{\"name\":\"Cancer diagnosis & prognosis\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-07-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11215449/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer diagnosis & prognosis\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21873/cdp.10353\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/7/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer diagnosis & prognosis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21873/cdp.10353","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
Global Immune-Nutrition-Information Index Is Independent Prognostic Factor for Gastric Cancer Patients Who Received Curative Treatment.
Background/aim: The aim of the present study was to evaluate the clinical impact of the Global Immune-Nutrition-Information Index (GINI) in patients with gastric cancer (GC) who received curative treatment and to clarify the potential of the GINI as a biomarker.
Patients and methods: Patients who underwent curative resection for GC at Yokohama City University between 2005 and 2020 were selected based on their medical records. The GINI was calculated as follows: GINI=[C-reactive protein × platelet × monocyte × neutrophil]/[albumin × lymphocyte].
Results: A total of 258 patients were included in this study. Of these, 169 patients were categorized into the GINI-low group and 89 into the GINI-high group using a cut-off value of 1,730. The three- and five-year overall survival (OS) rates were 86.4% and 78.4%, respectively, in the GINI-low group, and 66.4% and 58.3% in the GINI-high group (p<0.001). In a multivariate analysis for OS, the GINI was identified as an independent prognostic factor [hazard ratio (HR)=1.772; 95% confidence interval (CI)=1.053-2.979, p=0.031]. Similar results were observed for RFS. In addition, the GINI affected the perioperative clinical course, including postoperative surgical complications and postoperative adjuvant treatment.
Conclusion: The GINI is a promising biomarker for the treatment and management of GC.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
